Robyn L Marsh1, Ruth B Thornton2,3, Heidi C Smith-Vaughan1, Peter Richmond2,3, Susan J Pizzutto1, Anne B Chang1,4. 1. Child Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia. 2. School of Paediatrics and Child Health, University of Western Australia, Perth, Western Australia, Australia. 3. Telethon Institute for Child Health Research, Centre for Child Health Research, University of Western Australia, Western Australia, Australia. 4. Queensland Children's Respiratory Centre, Queensland Children's Medical Research Institute, Royal Children's Hospital, Brisbane, Queensland, Australia.
Abstract
BACKGROUND: The presence of Pseudomonas aeruginosa biofilms in lower airway specimens from cystic fibrosis (CF) patients is well established. To date, biofilm has not been demonstrated in bronchoalveolar lavage (BAL) from people with non-CF bronchiectasis. The aim of this study was to determine (i) if biofilm was present in BAL from children with and without bronchiectasis, and (ii) if biofilm detection differed between sequentially collected BAL. METHODS: Testing for biofilm in two sequentially collected BAL from children with and without bronchiectasis was done using BacLight™ live-dead staining and lectin staining for extracellular polymeric biofilm matrices. Bacterial culture and cytological measures were performed on the first and second lavages, respectively. Clinically important BAL infection was defined as >104 cfu of respiratory pathogens/ml BAL. RESULTS: Biofilm was detected in BAL from seven of eight (87.5%) children with bronchiectasis (aged 0.8-6.9 years), but was not detected in any of three controls (aged 1.3-8.6 years). The biofilms contained both live and dead bacteria irrespective of antibiotic use prior to bronchoscopy. Biofilm was detected more frequently in the second lavage than the first. Three of the seven biofilm-positive BAL were culture-positive for respiratory pathogens at clinically important levels. CONCLUSIONS: Biofilm is present in BAL from children with non-CF bronchiectasis even when BAL-defined clinically important infection was absent. Studies to characterize lower airway biofilms and determine how biofilm contributes to bronchiectasis disease progression and treatment outcomes are necessary. Pediatr Pulmonol. 2015; 50:284-292.
BACKGROUND: The presence of Pseudomonas aeruginosa biofilms in lower airway specimens from cystic fibrosis (CF) patients is well established. To date, biofilm has not been demonstrated in bronchoalveolar lavage (BAL) from people with non-CF bronchiectasis. The aim of this study was to determine (i) if biofilm was present in BAL from children with and without bronchiectasis, and (ii) if biofilm detection differed between sequentially collected BAL. METHODS: Testing for biofilm in two sequentially collected BAL from children with and without bronchiectasis was done using BacLight™ live-dead staining and lectin staining for extracellular polymeric biofilm matrices. Bacterial culture and cytological measures were performed on the first and second lavages, respectively. Clinically important BAL infection was defined as >104 cfu of respiratory pathogens/ml BAL. RESULTS: Biofilm was detected in BAL from seven of eight (87.5%) children with bronchiectasis (aged 0.8-6.9 years), but was not detected in any of three controls (aged 1.3-8.6 years). The biofilms contained both live and dead bacteria irrespective of antibiotic use prior to bronchoscopy. Biofilm was detected more frequently in the second lavage than the first. Three of the seven biofilm-positive BAL were culture-positive for respiratory pathogens at clinically important levels. CONCLUSIONS: Biofilm is present in BAL from children with non-CF bronchiectasis even when BAL-defined clinically important infection was absent. Studies to characterize lower airway biofilms and determine how biofilm contributes to bronchiectasis disease progression and treatment outcomes are necessary. Pediatr Pulmonol. 2015; 50:284-292.
Authors: Anne B Chang; Robyn L Marsh; John W Upham; Lucas R Hoffman; Heidi Smith-Vaughan; Deborah Holt; Maree Toombs; Catherine Byrnes; Stephanie T Yerkovich; Paul J Torzillo; Kerry-Ann F O'Grady; Keith Grimwood Journal: Front Pediatr Date: 2015-02-13 Impact factor: 3.418
Authors: Laia Fernández-Barat; Ana Motos; Otavio T Ranzani; Gianluigi Li Bassi; Elisabet Aguilera Xiol; Tarek Senussi; Chiara Travierso; Chiara Chiurazzi; Francesco Idone; Laura Muñoz; Jordi Vila; Miquel Ferrer; Paolo Pelosi; Francesco Blasi; Massimo Antonelli; Antoni Torres Journal: Microorganisms Date: 2017-09-20
Authors: Sara Marti; Carmen Puig; Alexandra Merlos; Miguel Viñas; Marien I de Jonge; Josefina Liñares; Carmen Ardanuy; Jeroen D Langereis Journal: mSphere Date: 2017-01-18 Impact factor: 4.389
Authors: Anne B Chang; John W Upham; I Brent Masters; Gregory R Redding; Peter G Gibson; Julie M Marchant; Keith Grimwood Journal: Pediatr Pulmonol Date: 2015-12-04